These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38772386)

  • 1. Modeling the Cost of Vaccinating a Measles Zero-Dose Child in Zambia Using Three Vaccination Strategies.
    Mak J; Patenaude BN; Mutembo S; Pilewskie ME; Winter AK; Moss WJ; Carcelen AC
    Am J Trop Med Hyg; 2024 Jul; 111(1):121-128. PubMed ID: 38772386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Added value of the measles-rubella supplementary immunization activity in reaching unvaccinated and under-vaccinated children, a cross-sectional study in five Indian districts, 2018-20.
    Prosperi C; Thangaraj JWV; Hasan AZ; Kumar MS; Truelove S; Kumar VS; Winter AK; Bansal AK; Chauhan SL; Grover GS; Jain AK; Kulkarni RN; Sharma SK; Soman B; Chaaithanya IK; Kharwal S; Mishra SK; Salvi NR; Sharma NP; Sharma S; Varghese A; Sabarinathan R; Duraiswamy A; Rani DS; Kanagasabai K; Lachyan A; Gawali P; Kapoor M; Chonker SK; Cutts FT; Sangal L; Mehendale SM; Sapkal GN; Gupta N; Hayford K; Moss WJ; Murhekar MV
    Vaccine; 2023 Jan; 41(2):486-495. PubMed ID: 36481106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the cost-effectiveness of different measles vaccination strategies for children in the Democratic Republic of Congo.
    Doshi RH; Eckhoff P; Cheng A; Hoff NA; Mukadi P; Shidi C; Gerber S; Wemakoy EO; Muyembe-Tafum JJ; Kominski GF; Rimoin AW
    Vaccine; 2017 Oct; 35(45):6187-6194. PubMed ID: 28966000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges Addressing Inequalities in Measles Vaccine Coverage in Zambia through a Measles-Rubella Supplementary Immunization Activity during the COVID-19 Pandemic.
    Yang Y; Kostandova N; Mwansa FD; Nakazwe C; Namukoko H; Sakala C; Bobo P; Masumbu PK; Nachinga B; Ngula D; Carcelen AC; Prosperi C; Winter AK; Moss WJ; Mutembo S
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of nationwide supplementary immunization in Lao People's Democratic Republic: Population-based seroprevalence survey of anti-measles and anti-rubella IgG in children and adults, mathematical modelling and a stability testing of the vaccine.
    Hachiya M; Miyano S; Mori Y; Vynnycky E; Keungsaneth P; Vongphrachanh P; Xeuatvongsa A; Sisouk T; Som-Oulay V; Khamphaphongphane B; Sengkeopaseuth B; Pathammavong C; Phounphenghak K; Kitamura T; Takeda M; Komase K
    PLoS One; 2018; 13(3):e0194931. PubMed ID: 29596472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the effect of measles and rubella mass vaccination campaigns on seroprevalence in India: a before-and-after cross-sectional household serosurvey in four districts, 2018-2020.
    Murhekar MV; Gupta N; Hasan AZ; Kumar MS; Kumar VS; Prosperi C; Sapkal GN; Thangaraj JWV; Kaduskar O; Bhatt V; Deshpande GR; Thankappan UP; Bansal AK; Chauhan SL; Grover GS; Jain AK; Kulkarni RN; Sharma SK; Chaaithanya IK; Kharwal S; Mishra SK; Salvi NR; Sharma S; Sarmah NP; Sabarinathan R; Duraiswamy A; Rani DS; Kanagasabai K; Lachyan A; Gawali P; Kapoor M; Shrivastava AK; Chonker SK; Tilekar B; Tandale BV; Ahmad M; Sangal L; Winter A; Mehendale SM; Moss WJ; Hayford K
    Lancet Glob Health; 2022 Nov; 10(11):e1655-e1664. PubMed ID: 36240831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of a Measles and Rubella Vaccination Campaign on Seroprevalence in Southern Province, Zambia.
    Carcelen AC; Mutembo S; Matakala KH; Chilumba I; Mulundu G; Monze M; Mwansa FD; Moss WJ; Hayford K
    Am J Trop Med Hyg; 2021 May; 104(6):2229-2232. PubMed ID: 33939639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age-specific prevalence of IgG against measles/rubella and the impact of routine and supplementary immunization activities: A multistage random cluster sampling study with mathematical modelling.
    Hachiya M; Vynnycky E; Mori Y; Do HT; Huynh MK; Trinh LH; Nguyen DD; Tran NAT; Hoang TT; Hoang HHT; Vo NDT; Le TH; Ichimura Y; Miyano S; Okawa S; Thandar MM; Yokobori Y; Inoue Y; Mizoue T; Takeda M; Komada K
    Int J Infect Dis; 2024 Jul; 144():107053. PubMed ID: 38641317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in measles control--Zambia, 1999-2004.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2005 Jun; 54(23):581-4. PubMed ID: 15959454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of three different vaccination strategies against measles in Zambian children.
    Dayan GH; Cairns L; Sangrujee N; Mtonga A; Nguyen V; Strebel P
    Vaccine; 2004 Jan; 22(3-4):475-84. PubMed ID: 14670330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of measles supplementary immunization activities on reaching children missed by routine programs.
    Portnoy A; Jit M; Helleringer S; Verguet S
    Vaccine; 2018 Jan; 36(1):170-178. PubMed ID: 29174680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
    Bae GR; Choe YJ; Go UY; Kim YI; Lee JK
    Vaccine; 2013 May; 31(24):2661-6. PubMed ID: 23602654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How much does it cost to measure immunity? A costing analysis of a measles and rubella serosurvey in southern Zambia.
    Carcelen AC; Hayford K; Moss WJ; Book C; Thuma PE; Mwansa FD; Patenaude B
    PLoS One; 2020; 15(10):e0240734. PubMed ID: 33057405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measles and rubella vaccination coverage in Haiti, 2012: progress towards verifying and challenges to maintaining measles and rubella elimination.
    Tohme RA; François J; Wannemuehler K; Magloire R; Danovaro-Holliday MC; Flannery B; Cavallaro KF; Fitter DL; Purcell N; Dismer A; Tappero JW; Vertefeuille JF; Hyde TB
    Trop Med Int Health; 2014 Sep; 19(9):1105-15. PubMed ID: 25041586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrating Blood Collection within Household Surveys: Lessons Learned from Nesting a Measles and Rubella Serological Survey within a Post-Campaign Coverage Evaluation Survey in Southern Province, Zambia.
    Mutembo S; Carcelen A; Mwansa FD; Searle K; Wanyiri JW; Book C; Thuma PE; Moss WJ; Hayford K
    Am J Trop Med Hyg; 2018 Dec; 99(6):1639-1642. PubMed ID: 30277204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measles and rubella serosurvey identifies rubella immunity gap in young adults of childbearing age in Zambia: The added value of nesting a serological survey within a post-campaign coverage evaluation survey.
    Hayford K; Mutembo S; Carcelen A; Matakala HK; Munachoonga P; Winter A; Wanyiri JW; Searle K; Mwansa FD; Mwiche A; Phiri C; Book C; Thuma PE; Moss WJ
    Vaccine; 2019 Apr; 37(17):2387-2393. PubMed ID: 30905529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using geospatial models to map zero-dose children: factors associated with zero-dose vaccination status before and after a mass measles and rubella vaccination campaign in Southern province, Zambia.
    Arambepola R; Yang Y; Hutchinson K; Mwansa FD; Doherty JA; Bwalya F; Ndubani P; Musukwa G; Moss WJ; Wesolowski A; Mutembo S
    BMJ Glob Health; 2021 Dec; 6(12):. PubMed ID: 34969682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of frequency and targeting of measles supplemental immunization activities in Nigeria: A cost-effectiveness analysis.
    Zimmermann M; Frey K; Hagedorn B; Oteri AJ; Yahya A; Hamisu M; Mogekwu F; Shuaib F; McCarthy KA; Chabot-Couture G
    Vaccine; 2019 Sep; 37(41):6039-6047. PubMed ID: 31471147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Who gets vaccinated in a measles-rubella campaign in Nepal?: results from a post-campaign coverage survey.
    Danovaro-Holliday MC; Rhoda DA; Lacoul M; Prier ML; Gautam JS; Pokhrel TN; Dixit SM; Rajbhandari RM; Bose AS
    BMC Public Health; 2022 Feb; 22(1):221. PubMed ID: 35114969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of supplementary immunization activities for measles: a stochastic model for Uganda.
    Bishai D; Johns B; Nair D; Nabyonga-Orem J; Fiona-Makmot B; Simons E; Dabbagh A
    J Infect Dis; 2011 Jul; 204 Suppl 1(Suppl 1):S107-15. PubMed ID: 21666151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.